This HTML5 document contains 185 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.2337/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33960291
rdf:type
wikibase:Item
schema:description
2014年論文 სამეცნიერო სტატია scienca artikolo article científic artigo científico (publicado na 2014) tudományos cikk artigo científico (publicado na 2014) บทความทางวิทยาศาสตร์ سائنسی مضمون scientific article wetenschappelijk artikel videnskabelig artikel (udgivet 2014) мақолаи илмӣ 2014年论文 2014年論文 artikull shkencor 2014 nî lūn-bûn vedecký článok wissenschaftlicher Artikel 2014年の論文 2014年论文 мақолаи илмӣ artigo científico 2014年论文 2014年論文 ২০১৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artículu científicu espublizáu en 2014 научная статья 2014年论文 vitskapeleg artikkel научни чланак مقالة علمية naučni članak mokslinis straipsnis teaduslik artikkel article scientifique (publié 2014) наукова стаття, опублікована у квітні 2014 artykuł naukowy artikulong pang-agham vitenskapelig artikkel vědecký článek 2014년 논문 article scientific 2014 թվականի ապրիլին հրատարակված գիտական հոդված מאמר מדעי επιστημονικό άρθρο 2014年论文 articol științific 2014年論文 vetenskaplig artikel bài báo khoa học tieteellinen artikkeli articolo scientifico 2014年论文 مقالهٔ علمی научни чланак 2014年論文 artículo científico publicado en 2014 2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած научна статия bilimsel makale
p:P577
wds:Q33960291-7D148192-9008-4361-94EC-E040DFA1292A
wdt:P577
2014-04-17T00:00:00Z
p:P407
wds:Q33960291-67F2BA3D-012B-46E1-996E-6A4F16A547FC
wdt:P407
wd:Q1860
p:P2860
wds:Q33960291-617D32B7-B8E4-4164-8F13-9F0F7640FB71 wds:Q33960291-6806AEDD-5F72-4A1E-A606-858DCA4FED79 wds:Q33960291-6C9CB3AF-F53E-4417-8248-EDF18E6BBD2A wds:Q33960291-5BDD4803-3313-4DDA-B860-121CDE49204A wds:Q33960291-5D55AB9B-474A-41D9-A579-3E817C142F77 wds:Q33960291-50319611-B91B-4E0D-B3EC-ADBF7DB6A99A wds:Q33960291-52A74A59-AED5-47EE-95CD-42BD47E1EB5A wds:Q33960291-3CC98B6E-A595-41CF-A931-6A90CF80CC48 wds:Q33960291-3E7A2744-9389-4778-8F64-53A72C83C273 wds:Q33960291-4598113E-21D3-4B36-BDA3-1AF01C9501BD wds:Q33960291-45CEA29B-47F7-47C3-AAC7-42C8ADF4989B wds:Q33960291-29DD1707-6E75-4272-BC63-D3EFAB52756B wds:Q33960291-29FAC749-F3B1-4D7B-B055-1377BED7D708 wds:Q33960291-2FD72DF4-0D72-44FE-891E-1472AE4C1566 wds:Q33960291-01B49A96-E6B2-4114-82E3-33C086A5A7DC wds:Q33960291-0F12E098-CCF9-4543-A2E9-EE0F503279B1 wds:Q33960291-11AEFA85-4958-4998-A7BD-7161E9034391 wds:Q33960291-27F406C0-5C96-4382-987C-3899BFF262D9 wds:Q33960291-01021905-30FE-43B0-BB05-2B143828E707 wds:Q33960291-E340D778-DC9F-4D0C-9705-D14F697B1A22 wds:Q33960291-FA4C5ADB-28E4-42B4-A1AD-48BBCC969D8E wds:Q33960291-DB019052-5750-41A0-B4F1-6700BD5470BD wds:Q33960291-DEF76F43-9AFF-41C9-A778-AFDAE289FEFE wds:Q33960291-D4C51A7C-F9CA-40BB-8FA4-BE04306B3BA4 wds:Q33960291-D59D5665-B837-4C2B-8B86-0CA59C49E5EF wds:Q33960291-A21C1AB9-341E-4E36-A7F0-1649FE532945 wds:Q33960291-A9EC04C6-B903-4370-B03C-8B595E434EDB wds:Q33960291-B88AAB28-21BA-42A7-81D3-0A5EC0471928 wds:Q33960291-9AEFE2A5-C7A1-422E-BCA5-B1FA86BE2426 wds:Q33960291-9DCA5471-4861-403E-9919-BBA1A151CD1F wds:Q33960291-9EE10082-265E-4B47-9C85-E0815C236C40 wds:Q33960291-876D24D5-5F00-4FC8-9CCC-D8ED13CF4E68 wds:Q33960291-8A28C7DC-E4CC-4EEB-B426-6729BE23A411 wds:Q33960291-7D3B22E4-9973-42C4-BA17-1CED48BAD156 wds:Q33960291-7E859FB9-4D3A-45F2-AAD5-E0060874B21E wds:Q33960291-830CB8D5-D592-4F26-A78B-C7A13B8E91B9 wds:Q33960291-74C62516-23FA-483B-9CAD-F942412351DC
wdt:P2860
wd:Q43054066 wd:Q51379684 wd:Q33799839 wd:Q51353951 wd:Q34598940 wd:Q37780573 wd:Q48274619 wd:Q45926533 wd:Q59624425 wd:Q36164602 wd:Q29617302 wd:Q37235840 wd:Q51381364 wd:Q24652963 wd:Q44865459 wd:Q37022597 wd:Q28373115 wd:Q79643921 wd:Q28263292 wd:Q36249636 wd:Q94706600 wd:Q43248899 wd:Q83248884 wd:Q28286240 wd:Q37377728 wd:Q46344895 wd:Q22241288 wd:Q38411245 wd:Q28285795 wd:Q43623564 wd:Q36108419 wd:Q58449388 wd:Q51484798 wd:Q36605779 wd:Q73135842 wd:Q43086322 wd:Q28273497
p:P2093
wds:Q33960291-7681265D-4B7C-49DD-BC5D-BB4AF293ED44 wds:Q33960291-7688C499-39C8-4498-8F9F-3BA1957AD413 wds:Q33960291-7070CBA3-9DE5-4F56-BA6C-9B74CA53D7BB wds:Q33960291-FE76B2C9-4955-4CB6-980F-AEFB25A692C1 wds:Q33960291-58F8E45E-95B3-4F6B-8370-3D0898F10843 wds:Q33960291-4B10F06B-0DB3-4932-AC47-6EFA17DC27E8
wdt:P2093
Michael Nauck Bruno Guerci Guillermo E Umpierrez Ruth S Weinstock Zvonko Milicevic Zachary Skrivanek
rdfs:label
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
skos:prefLabel
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
schema:name
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
p:P1476
wds:Q33960291-D1A9B5AD-7639-4A49-8380-4D59B4D7D830
wdt:P1476
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
p:P304
wds:Q33960291-DD5C0638-E24B-488F-ADD4-496EAA0D4882
wdt:P304
2149-2158
p:P31
wds:Q33960291-5D117AEA-4353-4FBD-AF7B-562EA6721924
wdt:P31
wd:Q13442814
p:P921
wds:Q33960291-D6AFD900-525F-4180-A231-337934148CE0 wds:Q33960291-522E0E00-4254-480A-B2EF-5C537DD5C17A
wdt:P921
wd:Q3025883 wd:Q1436668
p:P698
wds:Q33960291-3123149B-EF76-4C2D-9211-91FFC760744B
wdtn:P698
n12:24742660
wdt:P698
24742660
p:P1433
wds:Q33960291-C84C3DA5-1611-43FB-9DB1-20FB01F9A7B3
wdt:P1433
wd:Q5270111
p:P433
wds:Q33960291-85FB45C2-639F-442B-8BAD-61B7250D9888
p:P478
wds:Q33960291-90BD0424-0379-44F9-B079-071D383A55C6
wdt:P433
8
wdt:P478
37
p:P356
wds:Q33960291-A07D0A07-E1DF-4FB4-9D9B-553EF76734AC
wdtn:P356
n11:DC13-2761
wdt:P356
10.2337/DC13-2761
p:P932
wds:Q33960291-C23BBFFA-DCC9-472C-8B64-1B30B2834C67
wdt:P932
4113177